

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
06 February 2025 (06.02.2025)



(10) International Publication Number  
**WO 2025/026997 A1**

(51) International Patent Classification:  
C07D 471/04 (2006.01) A61K 31/435 (2006.01)  
A61P 35/00 (2006.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:  
PCT/EP2024/071506

**Published:**

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:  
30 July 2024 (30.07.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
23189307.4 02 August 2023 (02.08.2023) EP

(71) Applicant: **MERCK PATENT GMBH** [DE/DE]; Frank-  
furter Strasse 250, 64293 Darmstadt (DE).

(72) Inventors: **HEINRICH, Timo**; c/o Merck Healthcare  
KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE).  
**UNZUE LOPEZ, Andrea**; c/o Merck Healthcare KGaA,  
Frankfurter Strasse 250, 64293 Darmstadt (DE). **GUNERA,**  
**Jakub**; c/o Merck Healthcare KGaA, Frankfurter Strasse  
250, 64293 Darmstadt (DE). **BURGDORF, Lars**; c/o  
Merck Healthcare KGaA, Frankfurter Strasse 250, 64293  
Darmstadt (DE). **ALBERS, Lisa**; c/o Merck Healthcare  
KGaA, Frankfurter Strasse 250, 64293 Darmstadt (DE).  
**GAMBARDELLA, Alessia**; c/o Merck Healthcare KGaA,  
Frankfurter Strasse 250, 64293 Darmstadt (DE). **PE-**  
**TERSSON, Carl**; c/o Merck Healthcare KGaA, Frank-  
furter Strasse 250, 64293 Darmstadt (DE).

(74) Agent: **MERCK PATENT ASSOCIATION**; c/o Merck  
Patent GmbH, 64271 Darmstadt (DE).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: SUBSTITUED BICYCLIC HETEROCYCLIC YAP-TEAD AND/OR TAZ-TEAD INHIBITORS

(57) Abstract: The present invention relates to heterocyclic compound. These heterocyclic compounds are useful as TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of cancer and other severe disorders and diseases.

WO 2025/026997 A1